Searched for
VIATRIS PRICE
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...- Biocon to make Biocon Biologics a wholly owned subsidiaryBiocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Bioc...
- Biocon Biologics raises $300 million for debt refinancingThe loan was priced at 175 basis points above the three-month secured overnight funding rate (SOFR), which was trading at 4.59%. That pegs ...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon Biologics focusing on market share gains of biosimilars in key marketsBiocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...
- Kotak Fund to invest ₹1,600 crore in Nimmagadda Prasad's API businessKotak Strategic Situations Fund (KSSF) plans to invest around ₹1,600 crore in the active pharmaceutical ingredients (API) business acquired...
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Viatris puts India API business on the blockHowever, the API sale process, which was launched a couple of months ago, has seen no serious buyers, added multiple people aware of the de...
- Viatris cuts price of TB drug by 34%The decision to cut the price will help to expand access to a critical new treatment in more than 140 countries, including India, which has...
- Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar businessThe transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...
- Market movers: LIC shareholders lose Rs 77K crore in four days; Paytm gets 4% lift ahead of Q4 showLIC stock has fallen 13 per cent from its issue price of Rs 949 to Rs 826. In that process, shareholders of the company have lost over Rs 7...
- Biocon Biologics may close $3.34 billion Viatris deal in Q1Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum ...
- Biocon Biologics to raise $1.2 billion overseas loan for Viatris dealBiocon Biologics, a unit of Biocon, is raising $1.2 billion via an offshore loan with the pharmaceutical company likely appointing HSBC, MU...
- Is it time to turn contra & pick up Asian Paints & cement cos?“It is a bit early to conclude that the worst impact on some of the oil users be it paint companies or auto companies or cement companies i...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon to use debt, equity and IPO to buy Viatris biosimilars biz: Kiran Mazumdar Shaw“It will be a mix of debt, equity and of course IPO. It is going to be a very interesting business opportunity and a very comfortable aspec...
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...
- Biocon and Viatris to distribute Insulin Glargine through Walgreens in USWhile Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...
Load More
